Damough Shadi, Sabzalinezhad Masoumeh, Talebkhan Yeganeh, Nematollahi Leila, Bayat Elham, Torkashvand Fatemeh, Adeli Ahmad, Jahandar Hoda, Barkhordari Farzaneh, Mahboudi Fereidoun
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran; Department of Biotechnology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Protein Expr Purif. 2021 Mar;179:105805. doi: 10.1016/j.pep.2020.105805. Epub 2020 Dec 5.
Anti-TNF inhibitors exert their therapeutic effect by inhibition of the excessive amounts of TNF-α within the body. Recombinant TNF-α should be produced in a soluble refolded form to investigate the effectiveness and efficiency of anti-TNF-α compounds. In this research, the designed cassette was subcloned in the pET28a expression vector and expressed in E. coli BL21 (DE3). The identity of the protein was confirmed through SDS-PAGE and Western blotting. After optimizing expression conditions, protein purification was performed using native Ni-NTA affinity chromatography. The biological activity of the soluble recombinant TNF-α was investigated using MTT assay. Also, the affinity of an anti-TNF-α agent, Altebrel, was investigated against the expressed protein through ELISA. Optimization of TNF-α expression conditions represented that the highest expression could be achieved at 37 °C using 0.5 mM IPTG 6 h post-induction. The recombinant protein represented an inhibitory effect on the L929 murine fibroblast cell line and was successfully detected by Altebrel in ELISA. Binding kinetics were also studied using Cimzia as an anti-TNF-α molecule and 7.2 EM was calculated as the equilibrium dissociation constant value (K). The significant expression level of the recombinant protein in the soluble form, its high purity, and assessment of its biological activity showed that the expressed protein could be used in tests of ELISA and MTT to assess the activity of anti-TNF-α agents.
抗TNF抑制剂通过抑制体内过量的TNF-α发挥其治疗作用。重组TNF-α应以可溶性重折叠形式产生,以研究抗TNF-α化合物的有效性和效率。在本研究中,将设计的盒式结构亚克隆到pET28a表达载体中,并在大肠杆菌BL21(DE3)中表达。通过SDS-PAGE和蛋白质印迹法确认了蛋白质的身份。优化表达条件后,使用天然Ni-NTA亲和色谱法进行蛋白质纯化。使用MTT法研究了可溶性重组TNF-α的生物学活性。此外,通过ELISA研究了抗TNF-α药物Altebrel对表达蛋白的亲和力。TNF-α表达条件的优化表明,在诱导后6小时使用0.5 mM IPTG,在37°C时可实现最高表达。重组蛋白对L929小鼠成纤维细胞系具有抑制作用,并在ELISA中被Altebrel成功检测到。还使用Cimzia作为抗TNF-α分子研究了结合动力学,并计算出7.2 EM作为平衡解离常数(K)值。重组蛋白以可溶性形式的显著表达水平、高纯度及其生物学活性评估表明,表达的蛋白可用于ELISA和MTT试验,以评估抗TNF-α药物的活性。